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Abstract
Background: Transferrin receptor (TfR) is a cell membrane-associated glycoprotein involved in the cellular uptake
of iron and the regulation of cell growth. Recent studies have shown the elevated expression levels of TfR on
cancer cells compared with normal cells. The elevated expression levels of this receptor in malignancies, which is
the accessible extracellular protein, can be a fascinating target for the treatment of cancer. We have recently
designed novel type of immunotoxin, termed “hybrid peptide”, which is chemically synthesized and is composed
of target-binding peptide and lytic peptide containing cationic-rich amino acids components that disintegrates the
cell membrane for the cancer cell killing. The lytic peptide is newly designed to induce rapid killing of cancer cells
due to conformational change. In this study, we designed TfR binding peptide connected with this novel lytic
peptide and assessed the cytotoxic activity in vitro and in vivo.
Methods: In vitro: We assessed the cytotoxicity of TfR-lytic hybrid peptide for 12 cancer and 2 normal cell lines.
The specificity for TfR is demonstrated by competitive assay using TfR antibody and siRNA. In addition, we
performed analysis of confocal fluorescence microscopy and apoptosis assay by Annexin-V binding, caspase
activity, and JC-1 staining to assess the change in mitochondria membrane potential. In vivo: TfR-lytic was
administered intravenously in an athymic mice model with MDA-MB-231 cells. After three weeks tumor sections
were histologically analyzed.
Results: The TfR-lytic hybrid peptide showed cytotoxic activity in 12 cancer cell lines, with IC50 values as low as
4.0-9.3 μM. Normal cells were less sensitive to this molecule, with IC50 values > 50 μM. Competition assay using TfR
antibody and knockdown of this receptor by siRNA confirmed the specificity of the TfR-lytic hybrid peptide. In
addition, it was revealed that this molecule can disintegrate the cell membrane of T47D cancer cells just in 10 min,
to effectively kill these cells and induce approximately 80% apoptotic cell death but not in normal cells. The
intravenous administration of TfR-lytic peptide in the athymic mice model significantly inhibited tumor progression.
Conclusions: TfR-lytic peptide might provide a potent and selective anticancer therapy for patients.
Background
The transferrin receptor (TfR) is a cell-membrane-asso-
ciated glycoprotein involved in the cellular uptake of iron
and the regulation of cell growth [1]. Iron is a required
cofactor of heme and nonheme proteins involved in a
variety of cellular processes including metabolism and
DNA synthesis [2,3]. Therefore, various studies have
shown elevated levels of TfR expression on cancer cells
when compared with their normal counterparts [4-13].
Bladder-transitional cell carcinomas, breast cancer,
glioma, lung adenocarcinoma, chronic lymphocytic leu-
kemia, and non-Hodgkin’sl y m p h o m aa l s os h o w e d
increased TfR expression that correlated with tumor
grade and stage or prognosis [8,9,11-14]. These data sug-
gest that TfR expression may be increased on circulating
tumor cells, tumor precursor cells, or cells that have been
activated during tumorigenesis [15]. The elevated levels
of TfR in malignancies, its relevance in cancer, and the
extracellular accessibility of this molecule make it an
ideal candidate for the targeting of cancer cells.
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selective ligand chemically linked or genetically fused
to a toxin moiety. They can target cancer cells overex-
pressing tumor-associated antigens, membrane recep-
tors, or carbohydrate antigens [16,17]. Generally,
ligands for these receptors, monoclonal antibodies, or
single-chain variable fragments directed against these
antigens are fused with bacterial or plant toxins to
generate immunotoxins. Several such fusion proteins
including Pseudomonas exotoxin-based interleukin-4-
Pseudomonas exotoxin (IL4(38-37)-PE38KDEL) and
interleukin-13-Pseudomonas exotoxin (IL13-PE38QQR)
fusion proteins have been tested in clinical trials
[18,19]. Interleukin-2-diphtheria toxin fusion protein
(IL2-DT; Ontak™) is an FDA-approved fusion protein
[20,21].
However, bacterial- or plant-toxin-based chimeric pro-
teins pose several obstacles that limit their clinical appli-
cations [22], since the toxin part of these fusion proteins
elicits a high degree of humoral response in the human
body. Besides, in developed countries where people are
immunized against diphtheria, human serum will contain
circulating antibodies against diphtheria toxin, which will
result in neutralization of diphtheria-toxin-based immu-
notoxins [23,24]. At sufficiently high concentrations
these fusion proteins also lead to vascular leak syndrome
and show some degree of non-specific toxicity. In addi-
tion, the molecular size of these immunotoxins is gener-
ally greater than chemical compounds or fragment
antibody drugs, which might prevent drugs from effi-
ciently penetrating into larger tumor masses in the
human body.
As a new generation of immunotoxins, we have gener-
ated a chemically synthesized hybrid peptide, which is
composed of target-binding and cell-killing sequence
components. Papo and Shai [25] reported a new artifi-
cial cell-membrane-lytic peptide which kills tumor cells
better than normal cells. However, when this peptide
was fused to a molecular-targeted sequence the selectiv-
ity for cancer cells decreased considerably [25]. These
results prompted us to design a new lytic-type sequence
which is suitable for connecting to a molecular-targeted
sequence [26].
Utilizing a new lytic-targeted sequence, in this study
we designed a novel peptide targeting TfR, termed TfR-
lytic hybrid peptide, which is composed of a TfR-bind-
ing moiety and a cellular-membrane-lytic moiety using
the previous identification of peptide sequences binding
to TfR [27]. We demonstrated the selective cytotoxic
activity and characterized the cancer-cell-killing
mechanisms of this molecule, and, moreover, assessed
the antitumor activity of TfR-lytic peptide in xenograft
model in vivo.
Methods
Cell lines
Human breast cancer (BT474, T47D, SK-BR-3, MDA-MB-
231, BT20, and ZR75-1), glioblastoma (SN-19, and U251),
prostate cancer (LNCap), and pancreatic cancer
(COLO587) cell lines, were purchased from the American
Type Culture Collection (Manassas, VA, USA). Bile-duct
cancer cells (HuCCT-1) were purchased from Health
Science Research Resources Bank (Osaka, Japan). Glioblas-
toma (SF295) was obtained from the National Institutes of
Health (Bethesda, MD, USA). Primary hepatocyte ACBRI
3716 (HC) and pancreatic epithelial ACBRI 515 (PE) cells
were purchased from the European Collection of Cell Cul-
ture (Salisbury, UK). Cells were cultured in RPMI-1640
(BT474, T47D, MDA-MB-231, BT20, ZR75-1, SF295, SN-
19, U251, LNCap, COLO587, and HuCCT-1), CS-C (HC
and PE), or McCoy’s 5A (SK-BR-3) - with 10% FBS (Bio-
West, Miami, FL, USA), 100 μg/ml penicillin, and 100 μg/
ml streptomycin (Nacalai Tesque, Kyoto, Japan) added to
all media - under 5% CO2.
Peptides preparation and synthesis
The following peptides were purchased from Invitrogen
(Carlsbad, CA, USA) or SIGMA (St Louis, MO, USA).
Note that in both cases bold and underlined letters indi-
cate D-amino acids.
1. Lytic peptide: KLLLKLLKKLLKLLKKK
2. Transferrin receptor (TfR)-lytic hybrid peptide:
THRPPMWSPVWPGGGKLLLKLLKKLLKLLKKK
All peptides were synthesized by use of solid-phase
chemistry, purified to homogeneity (i.e. > 80%) by
reversed-phase high-pressure liquid chromatography,
and assessed by mass spectrometry. Peptides were dis-
solved in water.
Cell viability assay
A total of 3 × 10
3 cells per well were seeded into 96-well
plates and incubated for 24 h in medium containing 10%
FBS. The cells were then incubated with increasing con-
centrations of lytic peptide or the TfR-lytic peptide in
100 μl of medium for 72 h at 37°C. Cell viability was
measured using WST-8 solution (Cell Count Reagent SF,
Nacalai Tesque). For competition assays, the cells were
incubated with anti-TfR monoclonal antibody
(eBiosience) or mouse IgG isotype control for 3 h then
incubated with TfR-lytic hybrid peptide.
Immunofluorescence staining
TfR expression was determined using flow cytometry by
incubating 1 × 10
6 cells with a PE-conjugated human
monoclonal antibody to TfR (BD Biosciences San Jose,
CA, USA). All staining was performed at room tempera-
ture for 1.5 h. The cell fluorescence was measured by flow
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USA). The value of mean fluorescence intensity (MFI) was
determined using Win MDI version 2.9 software.
Confocal fluorescence microscopy
T47D cells were grown to 20% confluence on a glass-bot-
tomed dish for 24 h with a soluble fluorescent molecule,
calcein, which was added to the medium at a final con-
centration of 5 μM. Confocal images were taken after 5,
10, and 15 min after addition of TfR-lytic peptide using
an Olympus FV1000 confocal laser scanning microscope
(Olympus, Tokyo, Japan).
siRNA transfection
The following stealth RNA duplexes were synthesized by
Invitrogen:
TfR sense, 5’-AACAGAAAGAAACUGCUGG-
GAUUCC-3’,
TfR antisense, 5’-GGAAUCCCAGCAGUUUCUUU-
CUGUU-3’;
scramble sense, 5’-GCAUCGUACAGACAAUCUU-
CAGUUU-3’, and
scramble antisense, 5’-AAACTGAAGAUUGUCU-
GUACGAUGC-3’.
T47D and MDA-MB-231 cells were grown to 40%
confluence on a six-well plate, and then transfection of
these cells with siRNAs (100 pmol/ml) was performed
using Lipofectamine RNAi MAX (Invitrogen), according
to the manufacturer’s protocol.
Flow cytometry
T47D, and PE cells were treated for 3 h at 37°C with or
without TfR-lytic hybrid peptide or lytic peptide at
10 μM. For annexin V-propidium iodide (PI) and caspase
3&7-PI staining, cells were centrifugated and washed in
PBS. Then peptide-treated cultures were simultaneously
analyzed for annexin V-PI staining using the Annexin
V-Fluorescein Staining Kit (Wako, Osaka, Japan) and cas-
pase 3&7-PI staining using a carboxyfluorescein FLICA
caspase 3&7 assay (Immunochemistry Technologies,
Bloomington, MN, USA), by flow cytometry.
To analyse mitochondrial membrane potential, T47D
cells were labeled for 10 min with the mitochondrial-
membrane-potential-sensitive fluorescent dye JC-1 (Bio-
Vision Inc., Mountain View, CA, USA). After washing in
PBS samples were analyzed by flow cytometry to monitor
changes in the red/green fluorescence ratio to obtain the
index of mitochondrial membrane depolarization.
In vivo efficacy in xenograft models
Animal experiments were carried out in accordance
with the guidelines of Kyoto University School of
Medicine. Cells of the breast cancer cell line MDA-MB-
231 (5 × 10
6cells), resuspended in 150 μlo fP B S ,w e r e
transplanted subcutaneously into the flank region of
6-9-week-old athymic female nude mice weighing 17-21
g. When tumours reached 20-60 mm
3 in volume, ani-
mals were randomised into two groups, and saline (con-
trol) or TfR-lytic peptide (3 mg/kg) was injected
intravenously (50 μl/injection) three times a week for a
total of nine doses. Tumours were measured with a cali-
per and the tumour volume (in mm
3) was calculated
using the following formula: length × width
2 ×0 . 5 .A l l
values are expressed as the mean ± SD.
Results
The cytotoxic activity of TfR-lytic hybrid peptide is
dependent on cell-surface TfR expression levels
We first examined the correlation between cytotoxic
activity and the expression levels of TfR on the cell sur-
face using 12 cancer and 2 normal cell lines. As shown
in Figure 1A, treatment with the lytic peptide alone
induced dose-dependent cytotoxic cell killing in all can-
cer cell lines. However, molecular targeted TfR-lytic
hybrid peptide was superior in inducing cytotoxic activ-
ity in all cell lines. As shown in Table 1, the range of
IC50 values (the peptide concentration inducing 50%
inhibition of control cell growth) were 4.0-9.3 μMf o r
TfR-lytic hybrid peptide, whereas lytic peptide alone
induced modest cytotoxic activity with the IC50 value
ranging from 13.5 to 34.5 μM. A TfR-lytic hybrid pep-
tide concentration of merely 15-20 μM was sufficient to
induce more than 80% cell death in all cancer cell lines
examined (Figure 1A). These data suggest that cancer
cells are more susceptible (2.0-4.2-fold) to the TfR-lytic
hybrid peptide than to the lytic peptide alone.
We then assessed the cytotoxic activity of these pep-
tides in two normal cell lines. As shown in Figure 1B,
t w on o r m a lc e l ll i n e s ,H Ca n dP E ,h a r d l ys h o w e da n y
cell death at a peptide concentration of 40 μM, indicat-
ing that these normal cells were less sensitive to the
peptides than cancer cell lines.
The correlation between the IC50 values for these pep-
tides in cancer cells and normal cells was also assessed.
The expression levels of TfR for the 12 cancer cell lines
and two normal cell lines were assessed by flow cytometry
using a PE-conjugated anti-TfR monoclonal antibody. As
shown in Table 1, the MFI value for TfR monoclonal anti-
body in cancer cells ranged from 46.2 to 101.4, whereas
the MFI for the normal cells ranged from 2.8 to 35.5.
Thus, it was confirmed that these cancer cells express
more TfR than normal cell lines, as reported previously
(4-12). As shown in Figure 2, MFI value was not correlated
with IC50 of TfR-lytic hybrid peptide (r =- 0 . 6 7 ;F i g u r e2 A )
or lytic peptide alone (r = -0.47; Figure 2B). On the other
hand, MFI value correlated well with the ratio of IC50
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each cell line (r = 0.91; Figure 2C). These results suggest
that the increase in cytotoxicity that occurs when the TfR
moiety is combined to the lytic peptide is dependent on
cell-surface TfR expression levels.
To further confirm the specificity of the TfR-lytic
hybrid peptide to TfR, we performed a competition assay
using anti-TfR monoclonal antibody and siRNAs specific
to TfR. As shown in Additional file 1A, anti-TfR antibody
used in this study was not toxic to normal and cancer cell
lines (Additional file 1A). Either anti-TfR monoclonal
antibody or mouse IgG isotype control was added to the
T 4 7 Dc u l t u r e3hp r i o rt ot h ee x p o s u r eo ft h eT f R - l y t i c
hybrid peptide to assess the effect on cytotoxic activity.
As shown in Figure 3A, the inhibition of TfR-lytic-pep-
tide cytotoxic activity in T47D cells by TfR monoclonal
antibody was dose-dependent, whereas a significant
difference in cytotoxic activity with regard to antibody
concentration was not found with the mouse IgG isotype
control. The inhibition of cytotoxic activity by anti-TfR
or mouse isotype control antibody was not observed in
normal cell lines, PE and HC (Figure 3A and Additional
file 1B).
We also assessed whether cancer cells became less sensi-
tive to TfR-lytic hybrid peptide on reduction of TfR
expression by TfR-siRNA. The levels of target protein
in the cells were confirmed by flow cytometry analysis
(Figure 3B, inset graph). After transfection of TfR-siRNA
into T47D or MDA-MB-231 cells, these cells became less
sensitive to the cytotoxic effect of TfR-lytic hybrid pep-
tide (5 μM for T47D cells and 10 μM for MDA-MB-231
cells) compared with that of cells transfected with the
scramble-siRNA as a control (Figure 3B), and it was also
confirmed that siRNA used in this study was not toxic to
Figure 1 The cytotoxic activity of TfR-lytic hybrid peptide: (A) Twelve cancer cell lines were cultured with various concentrations of TfR-lytic
hybrid peptide or lytic peptide (0-30 μM) for 72 h, and cytotoxic activity was assessed using WST-8 reagent. (B) Two normal cell lines were
cultured with various concentrations of peptides (0-60 μM) for 72 h and cytotoxic activity was assessed. Absorbance values obtained with
untreated cells were set at 100%. Black and white squares indicate TfR-lytic hybrid peptide and lytic peptide, respectively. Data are represented
by means ± SD (bars) from triplicate determinations.
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and PE) as shown in additional file 2. These results sug-
gest that the binding of the TfR-lytic hybrid peptide to
TfR expressed on the cell surface is a critical requirement
for the induction of target-specific cell killing.
TfR-lytic hybrid peptide disintegrates the cancer cell
membrane to induce rapid killing of cancer cells
To explore the required duration of exposure to TfR-
lytic hybrid peptide to kill cancer cells, T47D, SKBR3,
BT20, U251, and HuCCT1 cells were treated with either
TfR-lytic hybrid peptide or lytic peptide alone for 0-24
hours. As shown in Figure 4A and Additional file 3A,
T47D, SKBR3 and BT20 cells, which were TfR overex-
pressed, maintained constant viability in the presence of
lytic peptide (10 μM) for all exposure times. In contrast,
t h ee x p o s u r eo fT f R - l y t i ch y b r i dp e p t i d e( 1 0μM)
resulted in time-dependent loss of viability in these
c e l l s ;am e r e1 0 - m i ne x p o s u r eo ft h eT f R - l y t i ch y b r i d
peptide to T47D, SKBR3, and BT20 cells was sufficient
Table 1 Cytotoxicity of peptides to various cell lines and TfR expression
Cell line IC50
Lytic peptide alone
(μM)**
TfR-lytic peptide
IC50Ratio
Lyttic/TfR-lytic
MFI*
mean
Statistical
Difference
vs HC
mean mean
Cancer cells Organ
BT474 Breast 34.5 ± 3.8 8.8 ± 3.3 3.9 99.9 ± 24.9 < 0.05
T47D Breast 14.1 ± 3.6 4.0 ± 0.2 3.6 101.4 ± 32.4 < 0.05
SK-BR-3 Breast 25.7 ± 0.6 6.5 ± 0.9 4.0 79.7 ± 21.2 < 0.05
MDA-MB-231 Breast 27.0 ± 1.5 7.8 ± 0.8 3.4 98.1 ± 23.9 < 0.05
BT20 Breast 20.0 ± 2.9 4.8 ± 0.4 4.2 91.5 ± 14.6 < 0.05
ZR75-1 Breast 19.4 ± 1.7 9.3 ± 2.6 2.1 46.4 ± 9.0 0.08
SF295 Brain 19.1 ± 2.9 6.3 ± 1.8 3.0 56.9 ± 17.6 0.08
SN19 Brain 21.9 ± 4.0 7.8 ± 0.5 2.8 75.3 ± 10.0 < 0.05
U251 Brain 17.0 ± 1.4 7.0 ± 2.0 2.4 56.3 ± 22.8 0.13
HuCCT-1 Bile duct 17.1 ± 2.8 8.3 ± 2.5 2.0 46.2 ± 4.6 < 0.05
LNCap Prostate 15.8 ± 1.5 6.2 ± 0.0 2.5 57.8 ± 5.9 < 0.05
COLO587 Pancreas 13.5 ± 1.2 6.4 ± 1.3 2.1 46.4 ± 15.8 0.18
Normal cells
Hepatocyte (HC) Liver 59.2 ± 5.0 54.7 ± 3.8 1.1 35.5 ± 4.2
Pancreatic epithelical (PE) cell Pancreas 59.6 ± 7.2 51.2 ± 3.6 1.2 2.8 ± 0.1
*MFI, mean fluorescence intensity; this is the extent of binding of the PE-conjugated anti-TfR monoclonal antibody to cells. The value of MFI is represented by
means ± SD from independent 3 time assays.
**The value of IC50 is represented by means ± SD from triplicate determinations, and the assay was repeated three times.
Figure 2 Enhancement of lytic-peptide cytotoxic activity by addition of the TfR-targeting moiety:I C 50 values of TfR-lytic hybrid peptide
(A) and lytic peptide alone (B) in normal and cancer cells, and the IC50 ratio of lytic/TfR-lytic hybrid peptide (C), are shown plotted against the
mean fluorescence intensity (MFI) of TfR expression.
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Page 5 of 13to kill more than 50% of cancer cells, and > 80% of cells
lost viability after 60 min. On the other hand, U251 was
induced more than 50% cell death at the concentration
of TfR-lytic10 μM in approximately 3 hours, and it took
more than 3 hours to induce enough cell death in
HuCCT1. It is suggested that the speed of peptide accu-
mulation to the cell membrane is slow in these TfR
low-expressed cell lines (Figure 4A).
Further, using confocal fluorescence microscopy we
assessed the interaction of TfR-lytic hybrid peptide with
the cancer cell membrane. When T47D cells were cul-
tured with the peptide (5 μM) for 0-15 min, a change of
cell-membrane shape (Figure 4B, arrowheads) and an
influx of calcein-labeled medium to the cancer-cell cyto-
sol (Figure 4B, arrows) was observed within 5 min (Fig-
ure 4B). Ten minutes later, it was found that > 50% of
cells had taken up calcein-labeled medium to the cyto-
sol. Thus, TfR-lytic hybrid peptide disintegrates the can-
cer cell membrane that induces killing as a result of cell
lysis. These results suggest that the TfR-lytic hybrid
peptide kills cells very rapidly by a lytic mechanism
upon binding to TfR.
Characterization of the cancer cell death mechanism by
TfR-lytic hybrid peptide
To determine whether the cytotoxic effect of TfR-lytic
hybrid peptide was due to the cell death including an
apoptotic cell death, cancer T47D and normal PE cells
were treated with TfR-lytic peptide (10 μM) or lytic
peptide alone (10 μM) for 3 h, and results were con-
firmed by annexin V-PI and caspase 3&7-PI staining
using flow cytometry. As shown in Figure 5A, the exter-
nalization of phosphatidylserine, an early event in the
apoptotic process, was analyzed with the annexin V-
binding assay. Treatment of T47D cells with TfR-lytic
peptide caused increase of annexin V positive cells (Fig-
ure 5A). Similar results were also obtained using other
cell lines such as MDA-MB-231, BT20, SKBR3, which
were TfR overexpressed cell lines as shown in additional
file 3B, and TfR-lytic peptide induced Annexin positive
Figure 3 Inhibition of cytotoxic activity of TfR-lytic hybrid peptide by anti-TfR antibody and knockdown using siRNA. (A) T47D and PE cells
were incubated with increasing concentrations of anti-TfR monoclonal antibody (TfR-Ab) or non-specific mouse IgG1 (isotype control) 3 h prior to TfR-
lytic peptide treatment at 5 μMa n d5 5μM, respectively. (B) T47D or MDA-MB-231 cells were transfected with TfR-siRNA or scramble-siRNA, and 4 days
after transfection, the levels of target protein in the cells were confirmed by flow cytometry analysis (inset graph). T47D and MDA-MB-231 cells were
treated with TfR-lytic at 5 μMa n d7 . 5μM respectively. Inhibition rate was assessed using WST-8 reagent. Data are represented by means ± SD (bars)
from triplicate determinations. Significance levels compared to the respective scramble-siRNA transfection: *, P <0 . 0 5 .
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Page 6 of 13Figure 4 The plasma membrane is permeable to TfR-lytic hybrid peptide, allowing rapid killing of cancer cells: (A) T47D, SKBR3, U251,
and HuCCT1 cells were treated with 10 μM of TfR-lytic hybrid peptide (black columns) or 10 μM of lytic peptide (white columns) for 0-24 hours,
and the cells were analyzed for cell viability using WST-8 reagent. The results are represented as means ± SD (bars) from triplicate
determinations. (B) Permeabilization of the cell membrane by TfR-lytic hybrid peptide in T47D breast cancer cells. Cells were observed in calcein
solution 0, 5, 10, and 15 min after addition of TfR-lytic peptide (10 μM). Arrows indicate penetrated cells and arrowheads indicate a change in
shape of the cell membrane by TfR-lytic peptide.
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Page 7 of 13Figure 5 Characterization of the cancer cell death mechanism by TfR-lytic hybrid peptide: (A) Cancer T47D and normal PE cells were
incubated with TfR-lytic peptide (10 μM) or lytic peptide (10 μM) for 3 h, then analyzed by dual-color flow cytometry for annexin V labeling and
propidium iodide (PI) staining. (B) T47D and PE cells were incubated with TfR-lytic peptide (10 μM) or lytic peptide (10 μM) for 3 h, then
analyzed by dual-color flow cytometry for caspase 3&7 and PI staining. Cell population values (%) are shown caspase 3&7-positive. The results are
represented as means ± SD (bars) from triplicate determinations. (C) T47D cells labeled with the mitochondrial-transmembrane-potential-sensitive
fluorescent dye JC-1 were treated with TfR-lytic peptide (upper panel) or lytic peptide (middle panel), or left untreated (lower panel), for 2 h, and
analyzed for transmembrane potential by flow cytometry.
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cent (Figure 5A and Additional file 3B), Whereas TfR-
lytic peptide also Annexin positive cells to U251 and
HuCCT1, which were TfR-low-expressed cell lines rela-
tively, the percentage of induced Annexin positive cells
by this hybrid peptide was lower than that of TfR over-
expressed cell lines (Additional file 3A). On the other
hand, the induction of apoptotic cell death was not
observed in PE cells treated with TfR-lytic peptide.
In addition, caspase 3&7 was detected by DEVD-FMK
covalent binding. As shown in Figure 5B, caspase 3&7
activation was detectable in T47D cells treated with
TfR-lytic peptide; the population of caspase 3&7-positive
cells was 89.1%. In contrast, the caspase 3&7-positive
populations in PE cells treated with TfR-lytic peptide
was 12.7%.
To further confirm the mechanism of apoptotic cell
death by TfR-lytic peptide, mitochondrial dysfunction
was assessed. T47D cells treated with TfR-lytic peptide
or lytic peptide were evaluated for changes in the mem-
brane potential of mitochondria by JC-1 staining. As
shown in Figure 5C, exposure of T47D cells to TfR-lytic
peptide resulted in a collapse of mitochondrial mem-
brane potential, whereas exposure to lytic peptide alone
had no influence on membrane potential. A tendency
like T47D was also observed in MDA-MB-231 (Addi-
tional file 3C). These results suggest that TfR-lytic
hybrid peptide induces cancer cell death by an apoptotic
mechanism via caspase 3&7 activation.
Antitumor activity of TfR-lytic peptide in vivo
To assess the antitumor effect of TfR-lytic peptide in a
xenograft model of human cancer, MDA-MB-231 cells,
which are TfR-overexpressing breast cancer cells were
implanted subcutaneously into athymic mice. TfR-lytic
peptide was injected intravenously at a dose of 3 mg/kg,
three times a week for a total of nine doses. The tumor
volume was inhibited significantly (P < 0.05) (Figure 6A).
As shown in Figure 6A, The tumor volume of MDA-MB-
231 on day 36 in the 3 mg/kg dosage group were reduced
to 42% (500 mm
3) of the control group with saline (1195
mm
3). No abnormalities were observed in peripheral
organs such as liver, kidney, and spleen in histological
examination (Figure 6B). There were no differences in
body weights and blood chemistries between the saline-
and TfR-lytic peptide-treated groups (data not shown).
Discussion
Therapeutic peptides are increasingly gaining popularity
for medicinal use in a variety of applications [28], includ-
ing tumor vaccines [29], antimicrobial therapy [30], and
nucleic acid delivery [31]. TfR-binding peptide was iden-
tified as both diagnostic and potential therapeutic pur-
poses by biopanning through sequential rounds of
negative and positive selection [27]. Several peptides
derived from phage-displayed peptide library screenings
have been developed into drug candidates and tested in
clinical trials, thus validating their peptide-targeting
potential [32]. Following this research, the development
of new peptide-based cancer therapeutics has been
undertaken [33]. It is also known that peptide therapeu-
tics are relatively easily generated using either recombi-
nant or solid-phase chemical synthesis techniques and
are generally less expensive than antibody-based thera-
peutics. In addition, because these peptides have lower
molecular weights than proteins there is less steric hin-
drance and the advantage of improved target accessibility.
In this study we linked two functional domains to pro-
d u c ean o v e lb i f u n c t i o n a lp e p t i d et h a tb i n d st oT f Rt o
cause lytic cell killing. It has been shown that the lytic
sequence utilized in this study has higher selectivity than
other lytic-type sequences thus far tested [25] in its dis-
crimination between normal and cancer membranes and
is suitable for chimerization with a targeting sequence.
Accordingly, the cancer selectivity of TfR-lytic hybrid
peptide designed in this study for TfR-expressing cancer
cells was confirmed in vitro (Table 1 and Figure 2). Due
to its targeting moiety, the hybrid peptide demonstrates
selective killing of cancer cells as swiftly as 10 min after
treatment (Figure 4A and 4B).
The TfR on normal cells is ubiquitously expressed at
low levels and is expressed at greater levels on cells with
a high proliferation rate, such as cells of the basal epider-
mis and intestinal epithelium [3-5]. Activated peripheral
blood mononuclear cells express high levels of TfR
[34-36]. In malignant tissues, TfR is expressed more
abundantly than in normal counterpart tissue [37].
Therefore, TfR could be a relevant target for molecular
targeted therapies against tumors.
The growth-inhibitory properties of anti-TfR antibodies
have been pursued since the 1980s [38,39]. Various anti-
bodies targeting TfR have shown different modes of action
in different models, including blocking of transferrin bind-
ing to the receptor [40], blocking the internalization of the
TfR-transferrin complex [41], downregulating cell-surface
TfR [42], or causing intracellular degradation of TfR [43].
However, as Ng et al. indicated, all anti-TfR antibodies
inhibit cell growth through iron deprivation [43]. Moura
et al. [44] and Ng et al. [45] also showed that treatment of
a neutralizing monoclonal antibody (mAb A24) and anti-
TfR-avidin fusion protein (anti-rat TfR IgG3-Av) for 48 h
and 96 h respectively, effectively inhibited proliferation of
cancer cells. However, in this study, our data demonstrate
that TfR-lytic peptide induces cancer cell-death as quickly
as 10-15 min after treatment (Figure 4A and 4B). We
hypothesize that the cytotoxic mechanism of TfR-lytic
peptide is initiated by binding of the TfR-binding moiety
of the hybrid peptide to TfR molecules on the cell surface,
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tially disintegrates the cancer cell membrane, induces
mitochondrial damage, and triggers apoptotic cell death.
Currently it is not clear how these lytic-type peptides
induce apoptotic cell death on the cell surface. In this
study, we demonstrated that TfR-lytic hybrid peptide
induced annexin V-PI- and caspase 3&7-PI-positive cells,
resulting in the collapse of mitochondrial membrane
potential in cancer cells. Active caspases 3&7 are effector
caspases activated by stimulation from mitochondria, cell-
surface receptors, and endoplasmic reticulum, and by
direct stimulation from stress-inducing molecules. In addi-
tion, we performed confocal fluorescence microscopy ana-
lysis and assessed the mitochondrial membrane potential
Figure 6 Antitumour activity of TfR-lytic peptide in tumour xenograft model in vivo: (A) MDA-MB-231 breast cancer cells were implanted
subcutaneously into athymic nude mice. Intravenous injection of either saline (control) or TfR-lytic peptide (3 mg/kg) was provided from day 5
as indicated by the arrows. Each group had six animals (n = 6), and experiments were repeated twice. Data are expressed as mean ± SD. (B)
Histological examination after treatment with TfR-lytic peptide. Images (× 400 magnification) of liver, kidney and spleen from mice after
treatment with saline (control) or TfR-lytic peptide (5 mg/kg) nine times were obtained by staining with hemaetoxylin and eosin (H&E).
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mulation of the cell surface, suggesting that these cascades
are all activated swiftly and simultaneously. Since TfR-lytic
peptide quickly disintegrates the cell membrane and accu-
mulates inside the cell, it is assumed that caspase cascades
occur simultaneously when the hybrid peptide is adminis-
tered. We measured the cytotoxic activity of TfR-lytic
hybrid peptide to various cancer cell lines in which the
expression levels of TfR are from high to low levels. The
fold cytotoxic activation of COLO587 and HuCCT1 by
TfR-lytic peptide was not so high, because the expression
levels of TfR in these cells were low. The enhancement of
cytotoxic activity by TfR-lytic peptide depends on the
expression levels of TfR in cell lines, suggesting that TfR-
lytic peptide is effectively targeted to cancer cell lines in
which TfR is expressed dominantly. In addition, as we
showed in Figure 4and additional file 3A, the speed of can-
cer cell killing by TfR-lytic peptide depends on the expres-
sion levels of TfR. We also previously showed that the
designed lytic peptide was suitable for the conjugation to
exert the enhancement of cytotoxic activity both in vitro
and in vivo [26].
Although it is suggested that peptides are relatively
easily inactivated by serum components in the human
body, it has been shown that diastereomeric peptides
are relatively free from inactivation in serum [46], and
that a lytic diastereomeric peptide administered intrave-
nously reduces tumor growth in an animal model of
human prostate cancer without rapid degradation of the
peptide in blood at a dose of 9 mg/kg [47]. Also, in our
previous study, it was found that EGFR-lytic hybrid pep-
tide targeting epidermal growth factor receptor (EGFR)
administrated intravenously reduced the growth of
EGFR-expressing tumor with a dose as low as 2 mg/kg
[26]. IC50 of TfR-lytic is 5-10 μM in vitro,w h i c hi s
approximately 18.5 to 37 mg/L. Given that a total blood
volume of the nude mice of about 20 g (body weight) is
1.5 ml, we expected that TfR-lytic may exert enough
antitumor effects at a dose of approximately 2.8 to
5.6 mg/kg. In this in vivo study, TfR-lytic-treated group
showed 42% of tumor growth-inhibitory effect at a dose
of 3 mg/kg. We demonstrated that this dose coincide
with that of expected from in vitro data.
So far, several drug candidates, including TfR antibody
42/6 and TfR-diphtheria immunotoxin, have shown lim-
ited antitumor activity without severe side effects in
clinical trials [48-50]. We expect that TfR-lytic hybrid
peptide may offer new options for TfR-targeted cancer
therapies. Standard therapy for malignant gliomas
usually includes surgical debulking or biopsy, external
beam radiation therapy, and systemic chemotherapy.
These treatments are incomplete because some tumor
cells are allowed to survive, leading to tumor progres-
sion or recurrence. TfR-lytic peptide, like all targeted
cytotoxins, offers the possibility of targeting these refrac-
tory tumor cells because malignant glioma cells express
TfR [50]. Our current in vitro results have shown a
clear dependence of the drug on the TfR moiety, sug-
gesting high selectivity for tumor cells and less cytotox-
ity toward normal cells. This selective targeting ability
should provide a large therapeutic window of opportu-
nity for targeting cancer cells over normal cells. Further
studies to confirm its efficacy, safety, and immunogeni-
city will broaden the indications of TfR-lytic hybrid pep-
tide for the future.
Conclusions
It was found that TfR-lytic peptide binds specifically to
TfR and selectively kills cancer cells and suggested that
TfR-lytic peptide penetrates the cancer cell membrane,
and induces rapid killing and apoptotic cell death. Further-
more, the intravenously administration of TfR-lytic pep-
tide in the athymic mice model significantly inhibited
tumor progression. TfR-lytic peptide might provide a
potent and selective anticancer therapy for patients.
Additional material
Additional file 1: Effect of anti-TfR antibody on the cell viability of
T47D, HC, and PE cells. (A) T47D, HC and PE cells were incubated with
increasing concentrations of anti-TfR monoclonal antibody (TfR-Ab) for 3
h, and the cytotoxicity was assessed using WST-8 reagent. Data are
represented by means ± SD (bars) from triplicate determinations. There
was no statistical difference in the viability between none treatment and
treatment with TfR-Ab 30 ng/mL. (B) HC cells were incubated with
increasing concentrations of anti-TfR monoclonal antibody (TfR-Ab) or
non-specific mouse IgG1 (isotype control) 3 h prior to TfR-lytic peptide
treatment at 55 μM. Inhibition rate of the cytotoxic activity was assessed
using WST-8 reagent. Data are represented by means ± SD (bars) from
triplicate determinations.
Additional file 2: Effect of knockdown of TfR by siRNA on the cell
viability of T47D, MDA-MB-231, HC and PEcells. (A) T47D, MDA-MB-
231, HC, and PE cells were transfected with TfR-siRNA scramble-siRNA or
none, and the cytotoxicity was assessed using WST-8 reagent. Data are
represented by means ± SD (bars) from triplicate determinations. There
was no statistical difference in the viability between none treatment and
treatetment with scramble- and TfR-siRNA. (B) HC and PE cells were
transfected with TfR-siRNA or scramble-siRNA, and 4 days after
transfection, cell viability was assessed using WST-8 reagent. Data are
represented by means ± SD (bars) from triplicate determinations.
Additional file 3: Characterization of cancer cell death induced by
TfR-lytic hybrid peptide. (A) BT20 cells were treated with the 10 μMo f
TfR-lytic hybrid peptide (black columns) or 10 μM of lytic peptide (white
columns) for 0-180 min, and the cells were analyzed for cell viability
using WST-8 reagent. The results are represented as means ± SD (bars)
from triplicate determinations. (B) MDA-MB-231, SKBR3, BT20, U251, and
HuCCT1 cells were incubated with TfR-lytic peptide (10 μM) and lytic
peptide (10 μM) for 3 h, and then analyzed by dual-color flow cytometry
for annexin V labeling and propidium iodide (PI) staining.(C) MDA-MB-
231 cells labeled with the mitochondrial-transmembrane-potential-
sensitive fluorescent dye JC-1 were treated with TfR-lytic peptide (right
panel) or lytic peptide (middle panel), or left untreated (left panel), for 2
h, and analyzed for transmembrane potential by flow cytometry.
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